What is Recipharm?
Established in 1995 and headquartered in Stockholm, Sweden, Recipharm operates as a key partner for pharmaceutical companies, offering comprehensive services that span the entire product lifecycle. From early-stage drug development to large-scale commercial manufacturing, Recipharm provides critical support, enabling its clients to bring vital medicines to market efficiently. The company's extensive infrastructure and expertise position it as a vital node in the global pharmaceutical supply chain, facilitating innovation and production for a diverse clientele.
How much funding has Recipharm raised?
Recipharm has raised a total of $612.4M across 8 funding rounds:
Share Placement
$20M
Debt
$101.3M
Stock Offering
$87M
Debt
$160.2M
Stock Offering
$29.5M
Debt
$106.8M
Stock Offering
$54.2M
Stock Offering
$53.4M
Share Placement (2011): $20M with participation from Nordea Funds
Debt (2012): $101.3M led by Swedbank AB
Stock Issuance/Offering (2014): $87M supported by Undisclosed
Debt (2014): $160.2M featuring DNB, Swedbank, and Handelsbanken
Stock Issuance/Offering (2016): $29.5M backed by Undisclosed
Debt (2016): $106.8M with participation from Undisclosed
Stock Issuance/Offering (2018): $54.2M led by Undisclosed
Stock Issuance/Offering (2020): $53.4M supported by Lansforsakringar, Polar Capital, and Gladiator
Key Investors in Recipharm
Lansforsakringar
Lansforsakringar is likely a Swedish insurance and financial services group, potentially providing strategic capital to established companies within its investment portfolio.
Polar Capital
Polar Capital is a global investment management firm, known for its expertise in various sectors, suggesting a focus on growth-oriented companies within the pharmaceutical or life sciences industry.
Gladiator
Gladiator, in the context of investment, could represent a private equity or venture capital firm specializing in providing substantial backing to companies with strong market potential and strategic value.
What's next for Recipharm?
The recent major strategic investment in Recipharm signals a strong confidence from the market in the company's trajectory and its role within the pharmaceutical industry. This influx of capital is likely to be directed towards enhancing manufacturing capacities, expanding research and development collaborations, and potentially pursuing strategic acquisitions to broaden its service offerings. As a CDMO, Recipharm is well-positioned to capitalize on the growing trend of pharmaceutical outsourcing, further solidifying its market leadership and driving future growth.
See full Recipharm company page
